2 Your Health: Pediatrician warns of coinfections in kids
'Pre-COVID we weren't always necessarily testing for a whole bunch of different viruses all at one time,' said Camille Sabella, MD, pediatric infectious disease specialist. 'But now that we're able to test for multiple viruses at one time and we're doing it more often, I think we're finding out that we're seeing a lot of coinfections.'
Dr. Sabella said coinfections can happen with many of the viruses circulating right now, which is why testing is important.
It helps with not only making a diagnosis but also determining treatment. And while being sick with two viruses may sound stressful, he said most kids tend to handle it pretty well and are able to recover at home.
Although in more severe cases, they may need to be hospitalized. Dr. Sabella said if your child has any kind of trouble breathing or seems to be getting worse with time, you should seek medical assistance.
As for prevention of these viruses, he recommends washing your hands.
'Alot of these viruses are really spread through the air, but the majority of the spread, like with RSV is through close contact. So, really being careful about strict hand washing is important. And when kids are sick, keeping them home from school and from daycare helps as well,' he advised.
If you or your child haven't been vaccinated yet, there's still time. Flu season, for example, usually goes until May.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
4 hours ago
- Business Wire
Hyperfine Announces First Patients Enrolled in PRIME Study Aimed at Accelerating Adoption of AI-Powered Portable MRI in Emergency Departments
GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable magnetic resonance imaging (MRI) system for the brain—the Swoop® system—today announced the enrollment of the first patients in the PRIME (Portable Rapid Imaging for Medical Emergencies) study. This study aims to evaluate the potential of AI-powered portable MRI technology to transform triage in the emergency department (ED) setting. "Given many EDs don't have ready access to MRI, this study could alter paradigms of advanced imaging access and utilization in the ED." The PRIME study at Yale School of Medicine builds on the ACTION PMR study, which demonstrated the utility of AI-powered portable MRI in the diagnosis and management of stroke patients in emergency department settings. Expanding the scope of patients studied, the PRIME study will include a broad and diverse set of patients presenting in an emergency department and assess the technology's potential effectiveness and efficiency as a triage tool for a wide range of brain-related emergency medical conditions. Unlike ACTION PMR, the PRIME study is being conducted using the recently released next-generation Swoop® system powered by Optive AI™ software. PRIME will be one of the first studies using the new software's advanced image quality that provides sharper anatomical detail, thus potentially enabling greater pathology detection. Hyperfine's portable MRI technology has established its value in healthcare institutions, providing high-quality brain imaging at the bedside for critically ill adult and pediatric patients. Timely access to MRI in emergency department settings is still a challenge for many hospitals. Prolonged patient boarding in EDs has been cited as the top priority for hospital leaders, as evidenced in the December 2024 article in Becker's Hospital Review 1. By removing the traditional barriers associated with access to conventional MRI scanners—such as wait times, shortage of dedicated MRI technologists, cost, and immobility—portable MR imaging enables faster, more efficient decision-making in emergency department settings. The PRIME study will enroll patients in a Level 1 emergency department, assessing a broad spectrum of emergency medical conditions. 'By evaluating the potential of portable MRI in this real-world setting, this study aims to determine if a portable MRI system can provide diagnostic imaging capabilities that can be quickly integrated into the ED workflow to improve patient care decisions in real time,' said Dr. Kevin Sheth, Professor of Neurology and Neurosurgery at the Yale School of Medicine and principal investigator for the PRIME study, who is working in close collaboration with his co-PI Dr. Adam De Havenon. 'Given many EDs don't have ready access to MRI, this study could alter paradigms of advanced imaging access and utilization in the ED,' said Dr. Charles Wira, Associate Professor of Emergency Medicine at Yale University. 'The Hyperfine portable MRI system could immediately provide ED clinicians and consulting physicians with critical imaging data at the point of care, helping them to make more informed, faster decisions when every second counts.' 'Hyperfine is thrilled to collaborate with Yale on this transformative project. The Yale team has worked with portable brain MRI since the technology's early days,' said Maria Sainz, President and CEO of Hyperfine. 'Through the PRIME study, they demonstrate a bold vision for how portable MRI can accelerate triage in emergency care. The next-generation Swoop® system, powered by Optive AI™ software, provides more clinically valuable image quality that we expect will drive greater adoption in the emergency setting and help address the widespread clinical and economic challenges of ED boarding.' Hyperfine is committed to advancing the role of portable MRI in emergency care of the brain, one of the sites of care where access to conventional MRI is challenging. The PRIME study represents a strategic initiative within the broader Hyperfine hospital market strategy to drive commercial growth, demonstrating how the placement of portable MRI systems in emergency departments can unlock timely diagnostic access and improve clinical workflows at the point of care. For more information about the Swoop® system, please visit For more information about the PRIME study, including enrollment details and eligibility criteria, please visit 1. ED boarding: 10 things to know. Becker's Hospital Review. About the Swoop® Portable MRI Systems The Swoop® Portable MR Imaging® Systems are U.S. Food and Drug Administration (FDA) cleared for brain imaging of patients of all ages. They are portable, ultra-low-field magnetic resonance imaging devices for producing images that display the internal structure of the head where full diagnostic examination is not clinically practical. When interpreted by a trained physician, these images provide information that can be useful in determining a diagnosis. About Hyperfine, Inc. Hyperfine, Inc. (Nasdaq: HYPR) is the groundbreaking health technology company that has redefined brain imaging with the Swoop® system—the first FDA-cleared, portable, ultra-low-field, magnetic resonance brain imaging system capable of providing imaging at multiple points of professional care. The mission of Hyperfine, Inc. is to revolutionize patient care globally through transformational, accessible, clinically relevant diagnostic imaging. Founded by Dr. Jonathan Rothberg in a technology-based incubator called 4Catalyzer, Hyperfine, Inc. scientists, engineers, and physicists developed the Swoop® system out of a passion for redefining brain imaging methodology and how clinicians can apply accessible diagnostic imaging to patient care. For more information, visit The Hyperfine logo, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. The Swoop logo, Optive AI logo, and Optive AI are trademarks of Hyperfine, Inc. Forward-Looking Statements This press release includes 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the 'Company') may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as 'expect,' 'estimate,' 'project,' 'budget,' 'forecast,' 'anticipate,' 'intend,' 'plan,' 'may,' 'will,' 'could,' 'should,' 'believes,' 'predicts,' 'potential,' 'continue,' and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under 'Risk Factors' therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.
Business Wire
4 hours ago
- Business Wire
Evolus Announces Publication of Independent Study in JAMA Dermatology Demonstrating Jeuveau ® as a Top Performer Among Leading Neurotoxins
NEWPORT BEACH, Calif.--(BUSINESS WIRE)-- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the publication of a landmark independent study in JAMA Dermatology directly comparing four leading botulinum toxin type A products for the treatment of glabellar lines: Jeuveau ® (prabotulinumtoxinA-xvfs), Botox ® (onabotulinumtoxinA), Dysport ® (abobotulinumtoxinA), and Xeomin ® (incobotulinumtoxinA). In the double-blind, randomized study conducted at the University of Pennsylvania, 143 female participants aged 30 to 65 were treated with FDA-approved doses of either Jeuveau ®, Botox ®, Dysport ®, or Xeomin ®. Using advanced 3-dimensional photogrammetry, researchers quantified dynamic facial strain to objectively measure efficacy at days 3, 30, 90, and 180. Key published findings include: Fast Onset of Action: Jeuveau ® and Dysport ® demonstrated significantly faster visible effects at Day 3 compared to Botox ® and Xeomin ®. Strong Peak Effect: Jeuveau ® achieved the highest peak effect at Day 30, with a median strain reduction of 93%, highlighting its robust performance profile. Long Duration of Effect: Jeuveau ® had significant duration at Day 180 compared with baseline and was significantly more effective than Botox ® at this time point. 'This is an important study as it was independently conducted and utilized a sensitive, validated endpoint designed to eliminate investigator bias in comparing the four neurotoxins,' said Dr. Rui Avelar, Chief Medical Officer and Head of R&D of Evolus. 'The results add to what we observed in our prior head-to-head study with Botox ®, while also offering valuable comparative insights across the broader landscape of aesthetic neurotoxins. The results reinforce what many aesthetic providers already observe in practice, that Jeuveau ® delivers a differentiated performance profile. These data support Jeuveau ® as a modern aesthetic neurotoxin delivering fast onset, strong effect, and long-lasting results.' Since its launch, Jeuveau ® has become the fastest-growing neurotoxin in the U.S. for four consecutive years. Today, it holds over 14% U.S. market share and has penetrated over 50% of aesthetic clinics. Evolus provided funding for this study through an investigator-initiated research grant. As an independent study, Evolus was not involved in the design, protocol development, or in the conduct of the research, each of which was carried out independently by the investigators. About Evolus, Inc. Evolus (NASDAQ: EOLS) is a global performance beauty company redefining the aesthetic injectable market for the next generation of beauty consumers through its unique, customer-centric business model and innovative digital platform. Our mission is to become a global leader in aesthetics anchored by our flagship products: Jeuveau ® (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics, and Evolysse ™, a collection of unique injectable hyaluronic acid (HA) gels. Visit us at and follow us on LinkedIn, X, Instagram or Facebook. Jeuveau ® and Nuceiva ®, are registered trademarks and Evolysse ™ is a trademark of Evolus, Inc. Botox ® (onabotulinumtoxinA) is a registered trademark of Allergan, Inc. Dysport ® (abobotulinumtoxinA) is a registered trademark of Ipsen Biopharma Limited. Xeomin ® (incobotulinumtoxinA) is a registered trademark of Merz Pharma GmbH & Co KGaA.
Business Wire
4 hours ago
- Business Wire
Vir Biotechnology Initiates Second Pivotal Trial in Its Global ECLIPSE Registrational Program for Chronic Hepatitis Delta
SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the enrollment of the first participant in the ECLIPSE 2 Phase 3 clinical trial, which is designed to compare the combination of tobevibart and elebsiran to continued bulevirtide monotherapy in participants with chronic hepatitis delta (CHD) who have not achieved undetectable hepatitis delta virus (HDV) RNA despite bulevirtide treatment. ECLIPSE 2 is one of three trials in Vir Biotechnology's registrational ECLIPSE program for CHD, which was initiated in March 2025. ECLIPSE 2 is designed to provide the registrational efficacy and safety data needed for potential submission to global regulatory agencies, including agencies in the U.S. and Europe. 'Patients living with chronic hepatitis delta, a known cause of liver cancer, are waiting for effective options to change the course of their disease." Share 'Patients living with chronic hepatitis delta, a known cause of liver cancer, are waiting for effective options to change the course of their disease,' said Marianne De Backer, Ph.D., MBA, Chief Executive Officer, Vir Biotechnology. 'We are excited about the rapid progress of our ECLIPSE program, which demonstrates our unwavering commitment to deliver a highly effective treatment for people living with chronic hepatitis delta.' 'We are encouraged by the transformational potential of tobevibart and elebsiran to rapidly drive the hepatitis delta virus to undetectable levels, as demonstrated by compelling data from our Phase 2 SOLSTICE clinical trial. We remain focused on advancing this investigational combination for chronic hepatitis delta with utmost urgency,' said Mark Eisner, M.D., M.P.H., Executive Vice President and Chief Medical Officer, Vir Biotechnology. CHD is the most severe form of chronic viral hepatitis, 1 with people living with the disease rapidly progressing to cirrhosis, liver failure 2 and liver-related death. 1 There are currently no approved treatments in the U.S., and options are limited in the European Union and globally. The objective of therapy is to eliminate the virus. Tobevibart in combination with elebsiran offers the potential to achieve this by tackling the viral lifecycle through multiple mechanisms. The significant unmet need in CHD and the potential for tobevibart and elebsiran to provide a much-needed treatment option has been recognized by the U.S. Food and Drug Administration (FDA) with Breakthrough Therapy and Fast Track designations, and by the European Medicines Agency (EMA) with Priority Medicines (PRIME) and orphan drug designations. About the ECLIPSE Registrational Program ECLIPSE is a registrational program to evaluate the safety and efficacy of tobevibart in combination with elebsiran in patients with chronic hepatitis delta (CHD). ECLIPSE includes three randomized, controlled trials designed to evaluate the combination therapy in comparison to deferred treatment or bulevirtide. ECLIPSE 1 (NCT06903338), a Phase 3 trial evaluating the safety and efficacy of tobevibart in combination with elebsiran compared to deferred treatment in the U.S. or other regions where bulevirtide use is limited, is currently recruiting. ECLIPSE 2 is a Phase 3 trial that will evaluate the efficacy and safety of switching to tobevibart and elebsiran in people with CHD who have not achieved viral suppression with bulevirtide therapy. ECLIPSE 1 and 2 are designed to provide the registrational efficacy and safety data needed for potential submission to global regulatory agencies. ECLIPSE 3 is a Phase 2b head-to-head trial to evaluate tobevibart and elebsiran compared with bulevirtide in bulevirtide-naïve patients, and it is designed to provide important supportive data to help establish access and reimbursement in key markets. ECLIPSE 2 plans to enroll participants in regions where bulevirtide is approved for the treatment of CHD. Participants who fail to achieve virologic suppression (defined as failure to achieve HDV RNA TND) after a minimum 24 weeks of bulevirtide treatment will be randomized 2:1 to switch to the combination of tobevibart and elebsiran or continue receiving bulevirtide. The primary endpoint in ECLIPSE 2 measures HDV RNA at the lower limit of quantification target not detected, HDV RNA TND (defined as HDV RNA = 0 IU/mL), at Week 24. About Tobevibart and Elebsiran Tobevibart is an investigational broadly neutralizing monoclonal antibody targeting the hepatitis B surface antigen (HBsAg). It is designed to inhibit the entry of hepatitis B and hepatitis delta viruses into hepatocytes and to reduce the level of circulating viral and subviral particles in the blood. Tobevibart was identified using Vir Biotechnology's proprietary monoclonal antibody discovery platform. The Fc domain has been engineered to increase immune engagement and clearance of HBsAg immune complexes and incorporates Xencor's Xtend™ technology to extend half-life. Tobevibart is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta. Elebsiran is an investigational hepatitis B virus-targeting small interfering ribonucleic acid (siRNA) discovered by Alnylam Pharmaceuticals, Inc. It is designed to degrade hepatitis B virus RNA transcripts and limit the production of hepatitis B surface antigen. Current data indicate that it has the potential to have direct antiviral activity against hepatitis B virus and hepatitis delta virus. Elebsiran is administered subcutaneously, and it is currently in clinical development for the treatment of patients with chronic hepatitis delta. About Vir Biotechnology, Inc. Vir Biotechnology, Inc., is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of infectious diseases and oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website. References: 1 WHO Hepatitis Delta Factsheet – Hepatitis D ( accessed June 2025 2 CDC What is Hepatitis D - FAQ | CDC, accessed June 2025 Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as 'should,' 'could,' 'may,' 'might,' 'will,' 'plan,' 'potential,' 'aim,' 'expect,' 'anticipate,' 'promising' and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements regarding: the therapeutic potential of the combination of tobevibart and elebsiran to treat CHD and Vir Biotechnology's belief that it can be a highly effective and transformative treatment option for these patients; Vir Biotechnology's clinical development plans and expectations for the ECLIPSE Phase 3 registrational program, including protocols for and enrollment into ongoing and planned clinical studies, target endpoints and data readouts; Vir Biotechnology's strategy and plans; and any assumptions underlying any of the foregoing. Many factors may cause differences between current expectations and actual results, including, without limitation: unexpected safety or efficacy data or results observed during clinical studies or in data readouts, including the occurrence of adverse safety events; risks of unexpected costs, delays or other unexpected hurdles; challenges in accessing manufacturing capacity; clinical site activation rates or clinical enrollment rates that are lower than expected; the timing and outcome of Vir Biotechnology's planned interactions with regulatory authorities, as well as general difficulties in obtaining any necessary regulatory approvals; successful development and/or commercialization of alternative product candidates by Vir Biotechnology's competitors, as well as changes in expected or existing competition; geopolitical changes or other external factors; and unexpected litigation or other disputes. In light of these risks and uncertainties, the events or circumstances referred to in the forward-looking statements may not occur. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early-stage clinical studies may not be indicative of full results or results from later stage or larger scale clinical studies and do not ensure regulatory approval. The actual results may vary from the anticipated results, and the variations may be material. You are cautioned not to place undue reliance on any scientific data presented or these forward-looking statements, which are based on Vir Biotechnology's available information, expectations and assumptions as of the date of this press release. Other factors that may cause Vir Biotechnology's actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Vir Biotechnology's filings with the U.S. Securities and Exchange Commission, including the section titled 'Risk Factors' contained therein. Except as required by law, Vir Biotechnology assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
